Market Overview
| Study Period | 2019 - 2030 |
|---|---|
| Base Year For Estimation | 2024 |
| Forecast Data Period | 2025 - 2030 |
| Market Size (2025) | USD 7.67 Billion |
| Market Size (2030) | USD 8.69 Billion |
| Growth Rate (2025 - 2030) | 2.54% CAGR |
| Market Concentration | Medium |
Major Players *Disclaimer: Major Players sorted in no particular order Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0. | |
Asia-Pacific Insulin Therapeutics Market Analysis by Mordor Intelligence
The Asia-Pacific Insulin Therapeutics Market size is estimated at USD 7.67 billion in 2025, and is expected to reach USD 8.69 billion by 2030, at a CAGR of 2.54% during the forecast period (2025-2030).
During the COVID-19 crisis, the Asia-Pacific diabetes market saw a gradual growth in demand for diabetic medications. According to a 2021 BeatO research on 800 participants, patients with COVID-19 and pre-existing diabetes suffered blood glucose level changes, resulting in a significant need for advanced diabetic medicines. To mitigate the disastrous impact of COVID-19, Novo Nordisk established a new social responsibility plan to combat diabetes, intending to provide patients in every nation with access to affordable diabetic care.
Diabetes patients, particularly those with Type 2 diabetes, have increased rapidly in Asian nations during the last few decades. Developing nations account for more than 70% of the worldwide diabetes population. The Asia-Pacific region is expected to develop significantly due to an aging population and rising diabetes prevalence, mostly due to increased stress, sedentary lifestyles, smoking, and excessive alcohol intake, which raises the body's sugar levels. Furthermore, the region's production base of key anti-diabetic medicine businesses aided market expansion. However, one of the primary constraining factors for the industry is the rising cost of pharmaceuticals.
The genetic factor is one of the primary reasons for the rapid spread of the disease. Sedentary lifestyles and obesity are the other factors responsible for the high prevalence of the disease. Although insulin has been used for treating diabetes for over 90 years, more than half of those who need insulin today still cannot afford and access it due to the high cost of the product.
Asia-Pacific Insulin Therapeutics Market Trends and Insights
Surge in APAC Diabetic Population is driving the market in forecast period
There would be a massive surge in the diabetic population in the Asia-Pacific region. The burden of diabetes is increasing, and it is expected to grow at a high rate in the Asia-Pacific region. The Asia-Pacific region dominates the diabetes market globally, contributing to 60% of the diabetes population. China and India have the highest diabetes population, especially type 2.
China has over 11% of its population suffering from diabetes, and in India, 5% suffers from diabetes. All Type 1 diabetes patients and a limited number of Type 2 diabetes patients require daily insulin injections as part of their treatment.
Poor healthcare infrastructure and utilization and lack of awareness about the disease in other countries of Asia-Pacific have complicated its prevalence. Furthermore, in these areas, most cases are uncontrolled or even undiagnosed until patients get symptoms of complications. Factors such as lack of awareness about the disease, unbalanced nutrition, and inadequate healthcare infrastructure and utilization are restraining the insulin market in the region.
As of 2022, the prevalence rates for diabetes ranged from 12% to 19% of the population in several countries in the region. Therefore, owing to the factors above, the growth of the studied Market is anticipated in the Market.
China dominates the Asia-Pacific Insulin Therapeutics Market
China is anticipated to hold the largest market share and is expected to maintain its dominant position during the forecast period, owing to huge patient pools and the ease in the regulatory process for insulin biosimilar drugs in the country. The incidence of type-2 diabetes (T2D) has rapidly increased over the recent decade, and T2D has become a leading public health challenge in China.
There is a considerable rise in the biosimilar drugs market in the Asia-Pacific, and China's Gan&Lee Basalin occupies almost 40% of the overall Glargine market. The country is witnessing a significant increase in generic drug manufacturers. Furthermore, the leading global players in the market studied faced intense competition from the regional players.
Diabetes is becoming an increasingly common condition in China. According to World Diabetes Day in 2030, there will be 643 million diabetics worldwide, the greatest amount. According to health professionals, urbanization, improving living standards, and an aging population are the main factors contributing to this spike. So, it is anticipated that during the coming several years, China's market for diabetes care will expand steadily.
Diabetes is a chronic illness that develops when the body either cannot use the insulin the pancreas makes effectively or cannot create any or enough of it. Type 1, Type 2 (the most prevalent kind), and gestational diabetes are the three primary subtypes of diabetes. Several early indications and symptoms of diabetes can be undetectable or modest. Almost two-thirds of diabetic patients in China were unaware of their illness and did not take any preventative steps. Diabetes that is left untreated can lead to major health issues like cardiovascular disease, chronic renal disease, and stroke.
All persons with type 1 diabetes, some people with type 2 diabetes, and some women who are pregnant who have diabetes need an ongoing supply of insulin. Novo Nordisk, the market leader in human insulin, controls the 20 billion yuan market for its analogs in China.
Competitive Landscape
The Asia-Pacific Insulin Therapeutics Market is highly consolidated, with three major manufacturers having a large market share. However, many local companies have brought biosimilar insulin at a much lower price. Mergers and acquisitions between the players in the recent past helped the companies strengthen their market presence. Sandoz partnered with Gan&Lee for the commercialization of insulin developed by Gan&Lee. Sandoz will likely fully commercialize these medicines in the EU, the United States, Switzerland, Japan, South Korea, Canada, Australia, and New Zealand.
Asia-Pacific Insulin Therapeutics Industry Leaders
Novo Nordisk
Eli Lilly
Sanofi
Biocon
Gan & Lee
- *Disclaimer: Major Players sorted in no particular order
Need More Details on Market Players and Competitors?
Download PDF
Recent Industry Developments
- September 2023: Meitheal Pharmaceuticals has secured the exclusive licensing rights from Tonghua Dongbao Pharmaceutical, a China-based company, to distribute three insulin biosimilars in the United States. These biosimilars consist of two rapid-acting insulins, insulin lispro and insulin aspart, as well as the long-acting insulin glargine. The parent company of Meitheal, Nanjing King-Friend Biochemical Pharmaceutical, has acquired these rights.
- March 2023: About three months after its approval for diabetes treatment, Hangzhou Zhongmei Huadong Pharma's Liraglutide Injection (Liluping) was also given the green light for obesity care.
Asia-Pacific Insulin Therapeutics Market Report Scope
Regular insulin is a kind of medical short-acting insulin, sometimes referred to as neutral and soluble insulin. Type 1 diabetes, Type 2 diabetes, gestational diabetes, and diabetic complications such as diabetic ketoacidosis and hyperosmolar hyperglycemic states are all treated with it. Asia-Pacific Insulin Therapeutics Market is segmented into Product Type and by Asia-Pacific. The market provides the value (in USD) and Volume (in ml) for the above-mentioned segments.
Drug
| Insulin | Basal or Long Acting Insulins | Lantus (Insulin Glargine) |
| Levemir (Insulin Detemir) | ||
| Toujeo (Insulin Glargine) | ||
| Tresiba (Insulin Degludec) | ||
| Abasaglar (Insulin Glargine) | ||
| Bolus or Fast Acting Insulins | NovoRapid/Novolog (Insulin Aspart) | |
| Humalog (Insulin Lispro) | ||
| Apidra (Insulin Glulisine) | ||
| FIASP (Insulin Aspart) | ||
| Admelog (Insulin Lispro) | ||
| Traditional Human Insulins | Novolin/Actrapid/Insulatard | |
| Humilin | ||
| Insuman | ||
| Insulin Combinations | NovoMix (Biphasic Insulin Aspart) | |
| Ryzodeg (Insulin Degludec and Insulin Aspart) | ||
| Xultophy (Insulin Degludec and Liraglutide) | ||
| Soliqua/Suliqua (Insulin Glargine and Lixisenatide) | ||
| Biosimilar Insulins | Insulin Glargine Biosimilars | |
| Human Insulin Biosimilars | ||
Geography
| Australia |
| China |
| India |
| Indonesia |
| Japan |
| Malaysia |
| Philippines |
| South Korea |
| Thailand |
| Vietnam |
| Rest of Asia-Pacific |
| Drug | Insulin | Basal or Long Acting Insulins | Lantus (Insulin Glargine) |
| Levemir (Insulin Detemir) | |||
| Toujeo (Insulin Glargine) | |||
| Tresiba (Insulin Degludec) | |||
| Abasaglar (Insulin Glargine) | |||
| Bolus or Fast Acting Insulins | NovoRapid/Novolog (Insulin Aspart) | ||
| Humalog (Insulin Lispro) | |||
| Apidra (Insulin Glulisine) | |||
| FIASP (Insulin Aspart) | |||
| Admelog (Insulin Lispro) | |||
| Traditional Human Insulins | Novolin/Actrapid/Insulatard | ||
| Humilin | |||
| Insuman | |||
| Insulin Combinations | NovoMix (Biphasic Insulin Aspart) | ||
| Ryzodeg (Insulin Degludec and Insulin Aspart) | |||
| Xultophy (Insulin Degludec and Liraglutide) | |||
| Soliqua/Suliqua (Insulin Glargine and Lixisenatide) | |||
| Biosimilar Insulins | Insulin Glargine Biosimilars | ||
| Human Insulin Biosimilars | |||
| Geography | Australia | ||
| China | |||
| India | |||
| Indonesia | |||
| Japan | |||
| Malaysia | |||
| Philippines | |||
| South Korea | |||
| Thailand | |||
| Vietnam | |||
| Rest of Asia-Pacific | |||
Need A Different Region or Segment?
Customize Now
Key Questions Answered in the Report
How big is the Asia - Pacific Insulin Therapeutics Market?
The Asia - Pacific Insulin Therapeutics Market size is expected to reach USD 7.67 billion in 2025 and grow at a CAGR of 2.54% to reach USD 8.69 billion by 2030.
What is the current Asia - Pacific Insulin Therapeutics Market size?
In 2025, the Asia - Pacific Insulin Therapeutics Market size is expected to reach USD 7.67 billion.
Who are the key players in Asia - Pacific Insulin Therapeutics Market?
Novo Nordisk, Eli Lilly, Sanofi, Biocon and Gan & Lee are the major companies operating in the Asia - Pacific Human Insulin Market.
What years does this Asia - Pacific Insulin Therapeutics Market cover, and what was the market size in 2024?
In 2024, the Asia - Pacific Insulin Therapeutics Market size was estimated at USD 7.48 billion. The report covers the Asia - Pacific Human Insulin Market historical market size for years: 2019, 2020, 2021, 2022, 2023 and 2024. The report also forecasts the Asia - Pacific Human Insulin Market size for years: 2025, 2026, 2027, 2028, 2029 and 2030.
